N-Gene
Szentistván, Borsod-Abauj-Zemplen, Hungary
About N-Gene
N-Gene is a developer of clinical-stage bio-pharmaceutical drugs designed to focus on the discovery, development, and commercialization of proprietary synthetic small molecules. The company's drugs use proprietary synthetic small molecule BGP-15 that has been found efficacious in various indications relating to adverse metabolic conditions, including type 2 diabetes mellitus by blocking JNK phosphorylation and has a new therapeutic effect via stress response modulation, enabling pharmaceutical companies to get a series of synthetic molecules to treat the insulin-resistance syndrome, improve cancer chemotherapy, and slow skin aging.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $3.0M
- Funding stage: Private Equity
- Last round: Private Equity (Feb 2009)
- Website: ngeneresearch.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/n-gene-2551172 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.